Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease

MT Newswires Live

Yesterday

Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.

The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.

The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.

LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2661127910"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2661127910\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2661127910?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-08-24 20:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2661127910","market":"fut","top_or_hot":-1,"title":"Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease","media":"MT Newswires Live","content":"<html><body><p> Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.</p><p>The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.</p><p>The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.</p><p>LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Biogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nBiogen, Eisai's LEQEMBI IQLIK Now Available in US for Early Alzheimer's Disease\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-08-24 20:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.</p><p>The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.</p><p>The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.</p><p>LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4585","symbol_name":"ETF&股票定投概念","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2661127910","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2661127910","pubTimestamp":1787576112,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Biogen  and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4585":"ETF&股票定投概念","LU0320765992.SGD":"FTIF - Franklin Biotechnology Discovery A Acc SGD","BIIB":"渤健公司","LU0234570918.USD":"高盛全球核心股票组合Acc Close","LU0889565916.HKD":"FRANKLIN BIOTECHNOLOGY DISCOVERY \"A\" (HKD) ACC","BK4139":"生物科技","IE00B894F039.SGD":"Legg Mason ClearBridge - US Aggressive Growth A Acc SGD-H","BK4532":"文艺复兴科技持仓","PBE":"INVESCO BIOTECHNOLOGY & GENOME ETF","BK4533":"AQR资本管理(全球第二大对冲基金)","BMED":"iShares Health Innovation Active ETF","LU0109394709.USD":"富兰克林生物科技新领域基金A (acc)","IE00B19Z9Z06.USD":"Legg Mason ClearBridge - US Aggressive Growth A Acc USD","BK4588":"碎股","IE00B19Z9P08.USD":"LEGG MASON CLEARBRIDGE US AGGRESSIVE GROWTH \"A\" (USD) INC"},"translate_title":"百健、卫材的 LEQEMBI IQLIK 现已在美国上市，用于治疗早期阿尔茨海默病","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PBE":0.6,"BIIB":1.5,"BMED":0.6},"content_text":"Biogen (BIIB) and Japanese pharmaceutical company Eisai said Monday that LEQEMBI IQLIK, a once-weekly autoinjector formulation of lecanemab-irmb, is now available in the US for initiation therapy in adults with early Alzheimer's disease.The treatment is indicated for patients with mild cognitive impairment or mild dementia due to Alzheimer's disease.The drug is administered using an autoinjector to provide 500 mg once a week in two consecutive 250 mg injections, with each injection taking about 15 seconds to deliver.LEQEMBI IQLIK is available through the LEQEMBI Specialty Pharmacy Network, the companies said.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}